Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
about
Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel diseaseCirculating fibroblast activation protein activity and antigen levels correlate strongly when measured in liver disease and coronary heart disease.Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP).Circulating fibroblast activation protein and dipeptidyl peptidase 4 in rheumatoid arthritis and systemic sclerosis.Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals a Core Set of Fibrosis-Specific Genes.
P2860
Lower serum fibroblast activation protein shows promise in the exclusion of clinically significant liver fibrosis due to non-alcoholic fatty liver disease in diabetes and obesity.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Lower serum fibroblast activat ...... sease in diabetes and obesity.
@en
type
label
Lower serum fibroblast activat ...... sease in diabetes and obesity.
@en
prefLabel
Lower serum fibroblast activat ...... sease in diabetes and obesity.
@en
P2093
P50
P1476
Lower serum fibroblast activat ...... sease in diabetes and obesity.
@en
P2093
A J Viera de Ribeiro
A S Veillard
E Cavanagh
K H Williams
N A Shackel
P304
P356
10.1016/J.DIABRES.2015.02.024
P577
2015-03-11T00:00:00Z